Oncoinvent sets regulatory strategy for development of Radspherin ®
Oncoinvent announced today that the regulatory strategy that will be used in the development of its lead product Radspherin® has been selected. The company has previously communicated that there are two equally attractive commercialization options available for Radspherin®. Due to Radspherin®’s inherent product characteristics the company has the option of either developing Radspherin as a medical device, or as a medicinal product. In the past, development of medical devices in Europe has traditionally taken significantly less time and has cost less than the development of medicinal